Juno files for IPO

Less than a year after Juno Therapeutics Inc. (Seattle, Wash.) debuted with a massive series A round, the cancer immunotherapy play is looking to go public. The company on Monday filed to raise up to $150 million in an IPO on NASDAQ underwritten by Morgan Stanley; JPMorgan; Goldman, Sachs; and Leerink.

Juno holds options to several autologous cancer immunotherapy programs -- including both chimeric antigen receptors (CARs) and T cell receptors (TCRs) -- from Memorial Sloan Kettering Cancer Center (MSKCC), Fred Hutchinson Cancer Research Center and Seattle Children's Research Institute. ...